

## **Natco Pharma Limited**

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.

Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243

CIN: L24230TG1981PLC003201, www.natcopharma.co.in

May 8, 2019

Corporate Relationship Department M/s. BSE Ltd.
Dalal Sreet, Fort
Mumbai 400 001

Manager – Listing M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra – Kurla Complex Bandra (E) <u>Mumbai 400 051</u>

Scrip Code: **Scrip Code: NATCOPHARM** 

Dear Sir

Please find enclose herewith the Press Release for your information.

Thanking you

Yours faithfully For NATCO Pharma Limited

M. Adinarayana

Company Secretary &

Vice President (Legal and Corp Affairs



## **Natco Pharma Limited**

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.

Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243

CIN: L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/2/2019 Press Release

## Natco's marketing partner Alvogen receives FDA approval for Nitroglycerin Sublingual Tablets

Hyderabad, India, May 8, 2019

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce that its marketing partner Alvogen has received the final approval of Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Nitroglycerin Sublingual Tablets USP, 0.3 mg, 0.4 mg, and 0.6 mg. Nitroglycerin sublingual tablets are used to treat episodes of angina (chest pain) in people who have coronary artery disease (narrowing of the blood vessels that supply blood to the heart).

Pfizer Pharmaceuticals Ltd markets this drug under its brand Nitrostat® Sublingual Tablets in the same strengths mentioned above.

As per IQVIA data, Nitroglycerin Sublingual Tablets had total annual sales of around USD 77.3 million in the US market, for the year ending 2018.

Forwarded for favour of publication For NATCO Pharma Limited

Marayana

M. Adinarayana
Company Secretary &
Vice President (Legal and Corp Affairs